Jiangsu Vcare Launches Phase II Trial for VC005 Topical Gel in Mild-to-Moderate Atopic Dermatitis
Published Time:
2025-03-26 18:05
Source:
On March 26, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) officially launched the Phase II clinical trial for its self-developed, highly selective JAK1 inhibitor VC005 gel for the topical treatment of mild-to-moderate atopic dermatitis (AD). The completed Phase I clinical study of VC005 gel demonstrated excellent safety and significant efficacy.
Currently, the oral tablet formulation of VC005 for moderate-to-severe AD has completed the first dosing of patients in Phase III clinical trials, with favorable safety results.
About VC005
VC005 is a novel, potent, and highly selective second-generation JAK1 inhibitor independently developed by Jiangsu Vcare. By selectively inhibiting JAK1, the drug reduces inflammatory responses and immune cell activation, making it clinically applicable for treating inflammatory and autoimmune diseases. Compared to the marketed leading drug Upadacitinib, VC005 exhibits lower JAK2 inhibitory activity (based on in vitro kinase assay results), potentially mitigating safety concerns associated with excessive JAK2 inhibition. The oral tablet formulation of VC005 is actively undergoing a Phase II clinical trial for ankylosing spondylitis and a Phase III trial for moderate-to-severe AD, which have yielded positive results. The topical gel formulation for mild-to-moderate AD has completed Phase I studies, demonstrating outstanding safety and efficacy.
About Atopic Dermatitis (AD)
Atopic dermatitis is a chronic, recurrent, inflammatory skin disease characterized by dry skin, intense itching, and eczematous rashes. The disease significantly impairs patients' quality of life. Epidemiologically, the global AD patient population is approximately 230 million, with an adult prevalence rate of 2%–8% in China, affecting over 70 million individuals. Among these, 67% are mild cases and 33% are moderate-to-severe. Frost & Sullivan predicts that the number of cases will grow at a compound annual growth rate (CAGR) of 1.7% from 2025 to 2030. Traditional treatments, such as glucocorticoids, are associated with numerous adverse reactions and limited long-term benefits, making disease control challenging. Meanwhile, topical JAK1 small-molecule targeted inhibitors, as non-glucocorticoid immunosuppressants, offer promising efficacy and safer choices for mild-to-moderate AD patients.
Related News
18
2018
/
04
Phase II Clinical Researcher Conference of Vicagrel was Successfully Held in Shenyang
On April 14, 2018, phase II clinical researcher conference of Vicagrel capsule, the 13th five-year national science and technology major project was successfully held in Shenyang. Clinical experts, institutional leaders and data management and statistical experts from 16 hospitals attended the meeting. Shenyang military region general hospital is the responsible hospital, and Yaling Han academician is the project leader.
View Details
29
2018
/
01
Jiangsu Vcare Held 2018 Annual Company Meeting
Jiangsu Vcare’s annual company meeting was held at Pearl Spring Hotel On January 21, 2018. All employees, partners and customers participated in the grand event.
View Details
26
2017
/
09
Jiangsu Vcare Organized an Emergency Response Training
On September 22, 2017, Vcare invited the teachers of Nanjing Science Education Center to teach company employees some emergency knowledge. There were more than 40 employees participated in the training. The main training contents included prevention for accidents, treatment for emergencies, emergency techniques for CPR on-site and first aid, work fatigue, prevention and improvement of common occupational diseases. Employees learned a lot from the training.
View Details
15
2017
/
09
Jiangsu Vcare’s New R&D Center and Headquarter are being constructed
Jiangsu Vcare Pharmaceutical Technology Co., Ltd. bought a 20 mu of land in Biomedical Valley, Nanjing High-tech Industrial Development Zone, Jiangbei New District on August 15, 2017. The area is equipped with metro line 3 and the subway S8. It is about 4 kilometers away from the Nanjing High-speed Railway North Station which is under construction. The surrounding environment is very beautiful and the traffic is very convenient. It is constructed as Vcare’s headquarter and drug research and development center and the center was put into use at the end of 2019.
View Details
31
2017
/
08
Jiangsu Vcare Held “Team Building Training” Activity
Jiangsu Vcare held “Team Building Training” activity in the town of Chaxi at the end of August. The activity was divided into several parts and each task is completed within specified time. Participants need to communicate and coordinate with team awareness.
View Details
31
2017
/
08
Jiangsu Vcare Held Ten Kilometers Run Activity
87 participants arrived at the main entrance of Xuanwu Lake to participate in a ten-kilometer running activity after warm-up at 7 o'clock on August 31. Six colleagues on a business trip in Hainan and seven colleagues on a business trip in Xi'an also actively participated in the running at the local. Everyone completed the ten-kilometer running after one hour and a half and was very happy to give a test to our physical fitness through the running.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn